Agilent Technologies, Inc.
$170.38-$4.96 (-2.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $39.1B
- P/E
- 30.0x
- EV / EBITDA
- 22.1x
- Revenue
- $6.9B
- Net margin
- 18.8%
- ROCE
- 15.3%
Price chart
Technical chartScreen technicals →+17.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -1.5%
- 3M
- +9.0%
- 6M
- +49.7%
- 1Y
- +17.5%
- 5Y
- +3.7%
52-week range
Day change -$4.96 (-2.8%) from $175 to $170 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in A, bought on each weekday since 2021.
News & filings
What Agilent Technologies filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity of 19.3% against a peer median of 23.0%.
Concerns (1)
- EV / EBITDA of 22.1 against a peer median of 13.0.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.
Read moreShow less
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
- Sector
- Healthcare
- Shares outstanding
- 283.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $39.1B
- P/E
- 30.0x
- P/B
- 5.8x
- EV / EBITDA
- 22.1x
- EV / Sales
- 5.8x
- P/S
- 5.6x
- 52-week high
- $181.48
- 52-week low
- $110.24
Profitability
- Operating margin
- 21.3%
- Net margin
- 18.8%
- EBITDA margin
- 26.4%
- ROE
- 19.3%
- ROCE
- 15.3%
- ROA
- 10.2%
- Asset turnover
- 0.55
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $6.9B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 6.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 0.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.2B
Solvency
- Current ratio
- 1.96
- Debt / Equity
- 0.50
- Debt / Assets
- 0.26
- CFO / Net profit
- 1.20
- Cash / Market cap
- 4.6%
Where the revenue went
Of every $100 of FY2025 revenue, $19 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $3.3B |
| Revenue | Gross profit | $3.6B |
| Gross profit | Research and development | $455.0M |
| Gross profit | Selling, general and administrative | $1.7B |
| Gross profit | Operating income | $1.5B |
| Operating income | Pretax income | $1.4B |
| Operating income | Interest and other expense | $44.0M |
| Pretax income | Tax and other | $132.0M |
| Pretax income | Net income | $1.3B |
Revenue and net profit
Revenue grew 6.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $6.8B | $1.3B |
| FY2023 | $6.8B | $1.2B |
| FY2024 | $6.5B | $1.3B |
| FY2025 | $6.9B | $1.3B |
Cash flows
FY2025: $1.6B from operations, $1.2B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.3B | $1.0B |
| FY2023 | $1.8B | $1.5B |
| FY2024 | $1.8B | $1.4B |
| FY2025 | $1.6B | $1.2B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $6.9B+6.7%1Y
- EBITDA
- $1.8B-2.1%1Y
- Net profit
- $1.3B+1.1%1Y
- Cash from operations
- $1.6B-11.0%1Y
- Free cash flow
- $1.2B-16.1%1Y
- Revenue CAGR, 3Y
- 0.5%
- Net profit CAGR, 3Y
- 1.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.9B | $1.8B | $1.3B | $1.2B | 19.3% | +6.7% | +1.1% |
Monthly returns
Month-by-month returns of A across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $12.7B |
| Current assets | $4.6B |
| Non-current assets | $8.1B |
| Liabilities | $6.0B |
| Current liabilities | $2.3B |
| Non-current liabilities | $3.6B |
| Equity | $6.7B |
| Paid-in capital | $5.6B |
| Retained earnings | $1.4B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; A highlighted.
P/E against peers
A trades at 30.0x earnings against a peer median of 30.0x.
Not shown (no positive earnings and no EV / Sales): Centene Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Agilent Technologies, Inc.Athis company | $39.1B | 30.0x | 5.8x | 19.3% | 22.1x |
| IDEXX Laboratories, Inc.IDXX | $44.5B | 42.0x | 27.7x | 66.0% | 30.1x |
| Humana Inc.HUM | $42.0B | 35.4x | 2.4x | 6.7% | — |
| Becton, Dickinson and CompanyBDX | $41.2B | 24.6x | 1.6x | 6.6% | 12.1x |
| Alnylam Pharmaceuticals, Inc.ALNY | $40.5B | 129.2x | 51.4x | 39.8% | 61.6x |
| Waters CorporationWAT | $37.0B | 57.5x | 14.4x | 25.1% | 36.7x |
| Zoetis Inc.ZTS | $33.3B | 12.5x | 10.0x | 80.2% | 9.9x |
| IQVIA Holdings Inc.IQV | $31.2B | 22.9x | 4.8x | 20.9% | 13.0x |
| Centene CorporationCNC | $31.0B | -4.6x | 1.6x | -33.4% | -6.5x |
| Peer median | — | 30.0x | 7.4x | 23.0% | 13.0x |
Year-to-date ROI
A since 1 January, against earlier years.
Historical volatility
A's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 23.6% |
| FY2023 | 19.8% |
| FY2024 | 22.9% |
| FY2025 | 21.3% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $6.9B |
| Cost of revenueCost Of Revenue | $3.3B |
| Gross profitGross Profit | $3.6B |
| Operating expensesOperating Expense | $2.2B |
| Research and developmentResearch And Development | $455.0M |
| Selling, general and administrativeSelling General And Administration | $1.7B |
| Total expensesTotal Expenses | $5.5B |
| Operating incomeOperating Income | $1.5B |
| Interest and other | |
| Pretax incomePretax Income | $1.4B |
| TaxTax Provision | $132.0M |
| Net incomeNet Income | $1.3B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $12.7B |
| Current assetsCurrent Assets | $4.6B |
| Non-current assetsTotal Non Current Assets | $8.1B |
| LiabilitiesTotal Liabilities Net Minority Interest | $6.0B |
| Current liabilitiesCurrent Liabilities | $2.3B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $3.6B |
| EquityTotal Equity Gross Minority Interest | $6.7B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.6B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.6B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.3B |
| Depreciation and amortisationDepreciation And Amortization | $288.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $288.0M |
| Stock-based compensationStock Based Compensation | $128.0M |
| Deferred taxDeferred Tax | -$130.0M |
| Deferred income taxDeferred Income Tax | -$130.0M |
| Operating gains and lossesOperating Gains Losses | $36.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $36.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Asset impairmentAsset Impairment Charge | $15.0M |
| Change in working capitalChange In Working Capital | -$131.0M |
| Other non-cash itemsOther Non Cash Items | $50.0M |
| Investing cash flowInvesting Cash Flow | -$394.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$394.0M |
| Capital expenditureCapital Expenditure | -$407.0M |
| Purchase of PP&EPurchase Of PPE | -$407.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$407.0M |
| AcquisitionsPurchase Of Business | — |
| DisposalsSale Of Business | $4.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $4.0M |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $8.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $8.0M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | $1.0M |
| Financing cash flowFinancing Cash Flow | -$715.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$715.0M |
| Debt issuedIssuance Of Debt | $4.0M |
| Debt repaidRepayment Of Debt | -$3.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$41.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | -$42.0M |
| Long-term debt issuedLong Term Debt Issuance | $4.0M |
| Long-term debt repaidLong Term Debt Payments | -$3.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $1.0M |
| Net common stock issuedNet Common Stock Issuance | -$425.0M |
| Common stock repurchasedCommon Stock Payments | -$425.0M |
| Share buybacksRepurchase Of Capital Stock | -$425.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $72.0M |
| Dividends paidCash Dividends Paid | -$282.0M |
| Common dividends paidCommon Stock Dividend Paid | -$282.0M |
| Other financing chargesNet Other Financing Charges | -$39.0M |
| Change in cashChanges In Cash | $450.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 900.0% |
| Cash at the start of the yearBeginning Cash Position | $1.3B |
| Cash at the end of the yearEnd Cash Position | $1.8B |
| Free cash flowFree Cash Flow | $1.2B |
| Supplemental |
Learn while you research
Academy chapters picked for Agilent Technologies, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read